Breaking down bone: New insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases

Genes and Development

Volumn 23, Issue 18, 2009, Pages 2117-2123

  Guise, Theresa A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone metastasis; Breast cancer; EGFR; Metalloprotease; Osteoclastogenesis

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CHEMOKINE RECEPTOR CXCR4; CONNECTIVE TISSUE GROWTH FACTOR; DENOSUMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN; SOMATOMEDIN; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA;

ANTINEOPLASTIC ACTIVITY; BONE DESTRUCTION; BONE MATRIX; BONE METASTASIS; BONE MINERALIZATION; BONE PAIN; BONE REMODELING; BONE STRENGTH; BREAST CANCER; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; MORBIDITY; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; UPREGULATION;

BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; METALLOPROTEASES; OSTEOLYSIS;

EID: 70349108389     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1854909     Document Type: Review

References (59)

1. Albain KS, Elledge R, Gradishar WJ, Hayes DF, Rowinsky E, Hudis C, Pusztai L, Tripathy D, Modi S, Rubi S. 2002. Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res Treat 76: S33. Abstract 20. doi: 10.1023/A:1021560101414.
2. Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC. 2008. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68: 92-104.
3. Bachmeier BE, Nerlich AG, Lichtinghagen R, Sommerhoff CP. 2001. Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity. Anticancer Res 21: 3821-3828. (Pubitemid 34229247)
4. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ. 2003. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 33: 28-37. (Pubitemid 36952685)
5. Body JJ, Lipton A, Gralow J, Steger GG, Gao G, Yeh H, Fizazi K. 2009. Effects of denosumab in patients with bone metastases, with and without previous bisphosphonate exposure. J Bone Miner Res. doi: 10.1359/jbmr.090810.
6. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE. 2005. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97: 59-69.
7. Coleman RE. 2009. Adjuvant bisphosphonates in breast cancer: Are we witnessing the emergence of a new therapeutic strategy? Eur J Cancer 45: 1909-1915.
8. Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MR. 2006. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 12: 3361-3367. (Pubitemid 43910880)
9. Costa LA, Alho I, Casimiro S, Oliveira AG, Luís I, Fernandes A, Bicho M, Ali SM, Leitzel K, Demers L, et al. 2008. Markers of bone turnover (ICTP, NTX) and serum matrix metalloproteinase 1 (MMP1) as prognostic markers in breast cancer patients (BC) with bone metastases (BM) treated with bisphosphonates (BP). J Clin Oncol 26 (Suppl.): Abstract 1024. http://meeting. ascopubs.org/cgi/content/abstract/26/15-suppl/1024.
10. Coussens LM, Fingleton B, Matrisian LM. 2002. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295: 2387-2392. (Pubitemid 34270240)
11. Crook MK, Guise TA. 2009. RANKL: Targeting bone and cancer to treat skeletal complications of malignancy. IBMS BoneKEy (in press).
12. Daubiné F, Le Gall C, Gasser J, Green J, Clézardin P. 2007. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 99: 322-330. (Pubitemid 47073494)
13. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, et al. 1999. RANK is essential for osteoclast and lymph node development. Genes & Dev 13: 2412-2424. (Pubitemid 29453612)
14. Egeblad M, Werb Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Natl Rev 2: 161-174. (Pubitemid 37328786)
15. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S. 2009a. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27: 1564-1571.
16. Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. 2009b. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: Results of a randomized phase II trial. J Urol 82: 509-515.
17. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. 1998. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139: 4743-4746. (Pubitemid 28487795)
18. Ibbotson KJ, Harrod J, Gowen M, D'Souza S, Smith DD, Winkler ME, Derynck R, Mundy GR. 1986. Human recombinant transforming growth factor a stimulates bone resorption and inhibits formation in vitro. Proc Natl Acad Sci 83: 2228-2232. (Pubitemid 16020868)
19. James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA. 2009. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: A double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 55: 1112-1123.
20. John A, Tuszynski G. 2001. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7: 14-22. (Pubitemid 32591662)
21. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, et al. 2006. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440: 692-696.
22. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J. 2003. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549. (Pubitemid 36808649)
23. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, et al. 2007. American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22: 1479-1491.
24. Klein A, Olendrowitz C, Schmutzler R, Hampl J, Schlag PM, Maass N, Arnold N, Wessel R, Ramser J, Meindl A, et al. 2009. Identification of brain- and bone-specific breast cancer metastasis genes. Cancer Lett 276: 212-220.
25. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, et al. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323. (Pubitemid 29061638)
26. Korpal M, Yan J, Lu X, Xu S, Lerit DA, Kang Y. 2009. Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med 15: 960-966.
27. Krane SM, Inada M. 2008. Matrix metalloproteinases and bone. Bone 43: 7-18.
28. Kumar S, Hand AT, Connor JR, Dodds RA, Ryan PJ, Trill JJ, Fisher SM, Nuttall ME, Lipshutz DB, Zou C, et al. 1999. Identification and cloning of a connective tissue growth factor-like cDNA from human osteoblasts encoding a novel regulator of osteoblast functions. J Biol Chem 74: 17123-17131. (Pubitemid 129519044)
29. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176. (Pubitemid 28180851)
30. Lipton A, Costa L, Ali S, Demers L. 2001. Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol 28: 54-59. (Pubitemid 32844930)
31. Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J. 2002. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: A comparison to pamidronate. Cancer Invest 20: 45-54. (Pubitemid 35303443)
32. Liu YJ, Xu Y, Yu Q. 2006. Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. Oncogene 25: 2452-2467.
33. Lorenzo JA, Quinton J, Sousa S, Raisz LG. 1986. Effects of DNA and prostaglandin synthesis inhibitors on the stimulation of bone resorption by epidermal growth factor in fetal rat long-bone cultures. J Clin Invest 77: 1897-1902. (Pubitemid 16062645)
34. Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, Massagué J, Kang Y. 2009. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes & Dev 23: 1882-1894.
35. Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK, Vargo-Gogola TC, Begtrup JL, Peterson TE, Fingleton B, et al. 2005. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 7: 485-496. (Pubitemid 40719131)
36. Mohammad KS, Chen CG, Balooch G, Stebbins E, McKenna CR, Davis H, Niewolna M, Peng XH, Nguyen DH, Ionova-Martin SS, et al. 2009. Pharmacologic inhibition of the TGF-β type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One 4: e5275. doi: 10.1371/journal.pone. 0005275.
37. Mundy GR. 2002. Metastasis to bone: Causes, consequences and therapeutic opportunities. Natl Rev 2: 584-593.
38. Nabha SM, Santos EB, Yamamoto HA, Belizi A, Dong Z, Meng H, Saliganan A, Sabbota A, Bonfil RD, Cher ML. 2008. Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner. Int J Cancer 122: 2482-2490. (Pubitemid 351590480)
39. Nakopoulou L, Katsarou S, Giannopoulou I, Alexandrou P, Tsirmpa I, Panayotopoulou E, Mavrommatism J, Keramopoulos A. 2002. Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients' survival in breast cancer. Mod Pathol 15: 26-34. (Pubitemid 34081456)
40. Nakopoulou L, Tsirmpa I, Alexandrou P, Louvrou A, Ampela C, Markaki S, Davaris PS. 2003. MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Res Treat 77: 145-155. (Pubitemid 36197615)
41. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R, Cher ML. 2002. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 94: 17-25. (Pubitemid 34082839)
42. Palmqvist P, Persson E, Conaway HH, Lerner UH. 2002. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-κB ligand, osteoprotegerin, and receptor activator of NF-łB in mouse calvariae. J Immunol 169: 3353-3362. (Pubitemid 35013185)
43. Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier Joffe E, Puricelli L. 2003. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 106: 745-751. (Pubitemid 36993399)
44. Roodman GD. 2004. Mechanisms of bone metastasis. N Engl J Med 350: 1655-1664.
45. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B. Zoledronic Acid Prostate Cancer Study Group. 2002. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94: 1458-1468.
46. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, et al. 1997. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89: 309-319. (Pubitemid 27199902)
47. Sugiura H, Yamada K, Sugiura T, Hida T, Mitsudomi T. 2008. Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 466: 729-736.
48. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman NI, Koh-Paige AJ, Shim H, et al. 2005. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 20: 318-329.
49. Takahashi N, MacDonald BR, Hon J, Winkler ME, Derynck R, Mundy GR, Roodman GD. 1986. Recombinant human transforming growth factor-α stimulates the formation of osteoclast-like cells in long-term human marrow cultures. J Clin Invest 78: 894-898. (Pubitemid 17177067)
50. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, Gillespie MT. 1999. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140: 4451-4458. (Pubitemid 30666108)
51. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K. 1997. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234: 137-142. (Pubitemid 27267548)
52. Upadhyay J, Shekarriz B, Nemeth JA, Dong Z, Cummings GD, Fridman R, Sakr W, Grignon DJ, Cher ML. 1999. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: Change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res 5: 4105-4110. (Pubitemid 30013792)
53. von Minckwitz G, Jonat W, Beckmann M, De Bois A, Kleeberg U, Kuhnie H, Kettner E, Hilfrich J, Torode J, Schneeweiss A. 2003. A multicenter phase II trial to evaluate gefitinib (Iressa, ZD1839) (500mg/day) in patients with metastatic breast cancer after previous chemotherapy treatment. Euro J Cancer 1: S133.
54. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massagué J, Mundy GR, Guise TA. 1999. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103: 197-206. (Pubitemid 29053137)
55. Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA. 2003. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci 100: 10954-10959. (Pubitemid 37140134)
56. Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerck YA, Mundy GR. 1997. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 99: 2509-2517. (Pubitemid 27227730)
57. Zampa G, Moscato M, Brannigan BW, Morabito A, Bell DW, Normanno N. 2008. Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib. Lung Cancer 60: 452-454.
58. Zhao W, Byrne MH, Wang Y, Krane SM. 2000. Osteocyte and osteoblast apoptosis and excessive bone deposition accompany failure of collagenase cleavage of collagen. J Clin Invest 106: 941-949. (Pubitemid 30800852)
59. Zhu J, Jia X, Xiao G, Kang Y, Partridge NC, Qin L. 2007. EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: Implications for osteolytic bone metastases. J Biol Chem 282: 26656-26664. (Pubitemid 47501956)